#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteochondrodysplasia NTRK gene fusion overexpression Intracranial calcification Hereditary motor and sensory neuropathy Oesophageal squamous cell carcinoma Mantle cell lymphoma Hyperoxaluria Hepato-lenticular degeneration Chronic hepatitis B Epilepsy with myoclonic-atonic seizures Thermal burn Chronic lymphocytic leukaemia refractory Vernal keratoconjunctivitis Adenovirus infection Focal segmental glomerulosclerosis More trials…

    Learn about Rare Diseases

    Erdheim-Chester disease – Diagnostics Lennox-Gastaut syndrome Systemic sclerosis pulmonary – Treatment MELAS syndrome Myelodysplastic syndrome with excess blasts Usher’s syndrome – Life with Disease Alagille syndrome CADASIL – Treatment Glomerulonephritis rapidly progressive Mucopolysaccharidosis III – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    FLUCLOXACILLIN SODIUM PRILOCAINE HYDROCHLORIDE Emactuzumab Mk-1084 Elvn-002-1 Emapalumab Poa Pratensis Imipenem Monohydrate Seladelpar Emavusertib Sodium Iodide (123 I) Dexrazoxane Isoprenaline Hydrochloride GAXILOSE Imipenem Busulfan Temocillin Sodium Metreleptin GSKVX000000034798 Tadekinig Alfa More therapies…

    Learn about Your Condition

    Connective tissue disorder Malignant mast cell neoplasm Congenital ureteric anomaly Asthma Liver disorder Arteriosclerosis Pulmonary venous thrombosis Cervix carcinoma stage I Sinusitis bacterial Pyrexia Skin wrinkling Diminished ovarian reserve Hepatotoxicity Paget's disease of the vulva Craniopharyngioma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Ankylosing spondylitis

  • A Study of Tulisokibart for Adults with Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

    Recruiting

    2 1
    Investigated Drugs:
    • Tulisokibart
    Germany The Netherlands Poland

  • Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

    Recruiting

    3 1 1 1 1
    Investigated Diseases:
    • Ankylosing spondylitis
    • Axial spondyloarthritis
    • Juvenile idiopathic arthritis
    Investigated Drugs:
    • Secukinumab
    Belgium Bulgaria Czechia Germany Italy Poland +2

  • Study on Upadacitinib for Adults with Active Axial Spondyloarthritis

    Not recruiting

    3 1
    Investigated Diseases:
    • Ankylosing spondylitis
    • Axial spondyloarthritis
    Investigated Drugs:
    • Abt-494
    Belgium Bulgaria Czechia France Germany Hungary +3

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!